ResearchSafe

Boswellia (AKBA) (Boswellia Serrata Extract (AKBA))

Category: Pain & Inflammation. Status: OTC supplement.

A standardized extract of Boswellia serrata (frankincense) whose active constituent AKBA provides a non-NSAID anti-inflammatory pathway. Biohackers use it for joint pain, gut inflammation, and as a natural alternative to chronic NSAID use.

How it works

AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining.

Key facts

  • Molecular weight: 512.7 Da (AKBA)
  • Half-life: ~6 hours (AKBA)
  • Bioavailability: Low; improved by AKBA-standardized and phytosome forms
  • Storage: Room temperature, protect from light and moisture.

Dosing overview

  • Typical dose: 100-250 mg AKBA-standardized, 1-2x daily
  • Frequency: 1-2x daily
  • Duration: Ongoing
  • Route: Oral capsule

Protocol notes

  • Look for extracts standardized to a high AKBA percentage rather than total boswellic acids.
  • Typical joint protocols use 100-250 mg AKBA once or twice daily with food.
  • Effects on chronic joint pain build over 2-4 weeks of consistent use.

Reported benefits

  • Reduces joint pain and stiffness
  • Non-NSAID (stomach-sparing) anti-inflammatory
  • Supports gut inflammation (IBD research)
  • Cartilage protection
  • Anti-inflammatory via 5-LOX inhibition

Possible side effects

  • Mild GI upset
  • Nausea
  • Rare skin rash
  • Possible additive effect with anti-inflammatories

Research

  • Boswellia AKBA for osteoarthritis (2020): AKBA-standardized extract significantly reduced pain and improved joint function versus placebo over 3 months.
  • Boswellia in inflammatory bowel disease (2019): Reduced inflammatory markers and symptoms in colitis models via 5-LOX inhibition.

Compare Boswellia (AKBA)

Research and educational reference only. Not medical advice.